Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Sales and Divestitures: 2015-2025

Historic Gains from Sales and Divestitures for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to $4.7 million.

  • Iovance Biotherapeutics' Gains from Sales and Divestitures rose 61.68% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 61.68%. This contributed to the annual value of $3.2 million for FY2024, which is 151.32% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Gains from Sales and Divestitures stood at $4.7 million for Q3 2025, which was up 12.31% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Gains from Sales and Divestitures ranged from a high of $4.7 million in Q3 2025 and a low of $770,257 during Q1 2023.
  • For the 3-year period, Iovance Biotherapeutics' Gains from Sales and Divestitures averaged around $2.2 million, with its median value being $1.3 million (2023).
  • Data for Iovance Biotherapeutics' Gains from Sales and Divestitures shows a peak YoY soared of 304.28% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Gains from Sales and Divestitures stood at $1.3 million in 2023, then skyrocketed by 151.32% to $3.2 million in 2024, then surged by 61.68% to $4.7 million in 2025.
  • Its Gains from Sales and Divestitures was $4.7 million in Q3 2025, compared to $4.1 million in Q2 2025 and $3.6 million in Q1 2025.